These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26385957)

  • 1. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    Eur Heart J; 2015 Dec; 36(46):3291-6. PubMed ID: 26385957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivabradine in stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy.
    Tendera M; Chassany O; Ferrari R; Ford I; Steg PG; Tardif JC; Fox K;
    Circ Cardiovasc Qual Outcomes; 2016 Jan; 9(1):31-8. PubMed ID: 26696613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the SIGNIFY trial.
    Grassi G
    Expert Opin Pharmacother; 2015; 16(12):1861-4. PubMed ID: 26153241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R
    Am Heart J; 2013 Oct; 166(4):654-661.e6. PubMed ID: 24093844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials.
    Mengesha HG; Weldearegawi B; Petrucka P; Bekele T; Otieno MG; Hailu A
    BMC Cardiovasc Disord; 2017 Apr; 17(1):105. PubMed ID: 28454527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
    Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
    Borer JS; Deedwania PC; Kim JB; Böhm M
    Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute ivabradine treatment reduces heart rate without increasing atrial fibrillation inducibility irrespective of underlying vagal activity in dogs.
    Uemura K; Inagaki M; Zheng C; Kawada T; Li M; Fukumitsu M; Sugimachi M
    Heart Vessels; 2017 Apr; 32(4):484-494. PubMed ID: 27844147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.
    Weeda ER; Nguyen E; White CM
    Ann Pharmacother; 2016 Jun; 50(6):475-85. PubMed ID: 26917820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
    Cammarano C; Silva M; Comee M; Donovan JL; Malloy MJ
    Clin Ther; 2016 Feb; 38(2):387-95. PubMed ID: 26839043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
    Borer JS; Swedberg K; Komajda M; Ford I; Tavazzi L; Böhm M; Depre C; Wu Y; Maya J; Dominjon F
    Cardiology; 2017; 136(2):138-144. PubMed ID: 27614723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
    Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
    [No Abstract]   [Full Text] [Related]  

  • 19. The Risk of Atrial Fibrillation With Ivabradine Treatment: A Meta-analysis With Trial Sequential Analysis of More Than 40000 Patients.
    Tanboğa İH; Topçu S; Aksakal E; Gulcu O; Aksakal E; Aksu U; Oduncu V; Ulusoy FR; Sevimli S; Kaymaz C
    Clin Cardiol; 2016 Oct; 39(10):615-620. PubMed ID: 27511965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of adding ivabradine to usual care in patients with angina pectoris: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.
    Maagaard M; Nielsen EE; Sethi NJ; Ning L; Yang SH; Gluud C; Jakobsen JC
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33046592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.